Skip to main content
α
中文
Back to research

Pfizer (PFE) stock analysis · Nov 2026

Updated regularlyUS stockHealthcare
Written Nov 9 (close at the time $29.39, 11/6)Latest close $27.40 (11/20)P/E (TTM) 39.1 · Next earnings 2027-02-02

At a glance

The core question that the current market is most concerned about is: whether Pfizer (PFE) stock price has shown signs of trend reversal during the short-term correction, and how well its high valuation matches the fundamental support.

Key research points

  • Short-term technical signals are weak: The closing price of $29.39 on November 6 fell about 2.7% from the previous high of $30.23, hitting an intraday low of $28.54. The middle track of the Bollinger Bands is $28.91, indicating that the price is close to the upper track pressure zone, and there is a risk of a retracement.
  • Overbought indicator prompts momentum exhaustion: On the 14th, the RSI reached 67.74, which is in the overbought area but has not entered the extreme level. Combined with the price falling from highs, it reflects the weakening of short-term upward momentum.
  • The mid-term trend is still bullish: The 50-day moving average of $28.19 and the 200-day moving average of $25.98 are both lower than the current price, indicating that the mid- to long-term trend is upward and there is no systematic breakdown.
  • Key support level tested: $28.54 is the recent low. If it falls below, it may open up downside space. $28.00 and $27.87 are subsequent psychological and historical support levels.
  • There is a significant deviation between the forward price-to-earnings ratio and actual profit expectations: The forward price-to-earnings ratio of 10.01 times implies future earnings per share of $2.94, but the real profit forecast is only about $0.25 per share, and the valuation basis faces the risk of reconstruction.
  • Strong free cash flow but high financial leverage: TTM free cash flow reached US$13.007 billion, supporting dividends and research and development, but the debt-to-equity ratio of 71.01% is higher than the warning line, and debt repayment pressure cannot be ignored.

Bull case

  • New drug pipeline progress brings emotional support: Paxlovid was approved for prevention in high-risk groups in China, and positive clinical data of Lecanemab Alzheimer's disease drug drove the market's positive expectations for R&D breakthroughs.
  • The attractiveness of high dividends continues to show: The dividend rate of 5.85% is significantly higher than the industry average. Combined with abundant free cash flow, it constitutes an important value anchor for long-term holders.
  • Forward valuation has potential for repair: If future profits return to expected levels (such as the successful commercialization of new drugs), the current forward price-to-earnings ratio of 10 times may become the starting point for valuation repair.

Cautious view

  • Weak growth in main business: Annual revenue dropped from $170.1B in Q3 2025 to $159.8B in Q3 2026, showing that the core product line is facing a patent cliff and competitive pressure.
  • Valuation logic is fragile: The PEG ratio is as high as 9.1, which is far beyond the reasonable range. If the profit growth rate cannot match, the stock price will face systemic adjustments.
  • Financial structure under pressure: Although free cash flow is sufficient, net debt reaches US$60.847 billion, and the debt-to-equity ratio is high at 71.01%, which is sensitive to interest rate changes and revenue fluctuations.

Risks

  • Policy Risk: The U.S. Medical Insurance Negotiation Act extends to high-priced innovative drugs, and China's medical insurance access is slow, which may limit the commercialization space of new drugs.
  • Competition Risk: Generic drug licensing negotiations and the efficacy advantages of competing products may erode Pfizer's market share of existing products.
  • Financial Risk: High debt levels may exacerbate debt service pressures when interest rates rise or revenue declines.
  • Performance realization risk: The commercialization progress of new drugs depends on clinical data verification and regulatory approval, and there may be delays or failures.
  • Valuation Bubble Risk: The current price-to-earnings ratio of 41.99 times and PEG 9.1 seriously deviate from the normal level. Once profits fall short of expectations, there will be significant correction pressure.

Metrics to watch

  • New drug commercialization revenue data: Focus on the actual sales revenue of new drugs such as Paxlovid and Lecanemab in the third quarter financial report of 2026 to determine whether the market penetration rate is in line with expectations.
  • Medical Insurance Negotiation Results: The preliminary results of China's medical insurance negotiations were announced on November 20, which will directly affect the accessibility and pricing strategies of related drugs.
  • Free cash flow and net profit trend comparison: Track whether free cash flow continues to improve in the next quarter, and whether net profit can recover from the impact of non-recurring losses.
  • Federal Reserve Interest Rate Policy Trends: If the interest rate hike cycle ends or turns to interest rate cuts, it will reduce corporate financing costs and benefit highly indebted pharmaceutical companies.
  • Technical key price breakthrough situation: Whether the $28.54 support level is effectively held, if it falls below, it may trigger a further downward trend; whether the $30.23 high can be challenged again will determine the short-term trend direction.

Regularly updated · want it fresher? Sign up for 3 free on-demand reports

US, Hong Kong and China ADR names alike. Understand what happened to a company recently and why — the decision is yours.

This page is research and explanation. It is not directed at any individual's investment decision and is not investment advice. Investing involves risk.

Latest earnings brief: Q3 2026 →

Related: Healthcare

Other research in the same sector and market, to put PFE in context.

AbbVie
ABBV · Healthcare
Amgen
AMGN · Healthcare
Intuitive Surgical
ISRG · Healthcare
Gilead
GILD · Healthcare
UnitedHealth
UNH · Healthcare
Eli Lilly
LLY · Healthcare
See all 150 stock research pages → · Research hub · Earnings briefs